Edgar Filing: ALLERGAN INC - Form 4

ALLERGAN Form 4										
May 07, 201	ПЛ								PPROVAL	
	UNITED	STATES		RITIES A Ashington			E COMMISSIO	N OMB Number:	3235-0287	
Check th if no lon subject t Section Form 4 of Form 5 obligation may con <i>See</i> Instr 1(b).	ger o 16. or Filed pu tinue.	rsuant to S (a) of the F	Section Public U	SECUI 16(a) of th Jtility Hol	RITIES ne Securi ding Co	ities Excha	WNERSHIP OF inge Act of 1934, t of 1935 or Secti 1940	Estimated burden hou response	urs per	
(Print or Type	Responses)									
1. Name and A Dunsire De	Person <u>*</u>	2. Issuer Name and Ticker or Trading Symbol ALLERGAN INC [AGN]				5. Relationship of Reporting Person(s) to Issuer				
(Last) 2525 DUPC	(Last) (First) (Middle) 2525 DUPONT DRIVE			of Earliest T Day/Year) 2014	ransaction	I	(Check all applicable) <u>X</u> Director Officer (give title 10% Owner below) Other (specify below)			
(Street) IRVINE, CA 92612			4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
(City)	(State)	(Zip)	Tak	ale I - Non-	Dorivativa	Securities	Person Acquired, Disposed	of or Boneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	-	ed Date, if	3. Transactic Code (Instr. 8) Code V	4. Securi nAcquirec Disposec (Instr. 3,	ties I (A) or I of (D) 4 and 5) (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect	
Reminder: Rep	port on a separate line	e for each cla	ass of sec	urities bene	Perse infor requi	ons who re mation con red to resp ays a curre	or indirectly. spond to the colle tained in this form ond unless the fo ently valid OMB co	n are not rm	GEC 1474 (9-02)	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number	6. Date Exercisable and	7. Title and Amount of	8. Pric
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	onof Derivative	Expiration Date	Underlying Securities	Deriva
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	Securi
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Acquired			(Instr.

Edgar Filing: ALLERGAN INC - Form 4

Code V (A) (D) Date Expiration Title Amount Exercisable Date or
Number of Shares
A $\frac{17.76}{(2)}$ $\frac{(3)}{(3)}$ $\frac{(3)}{(3)}$ Common 17.76 \$ 10
A $\frac{15.03}{(2)}$ $\frac{(3)}{(3)}$ $\frac{(3)}{(3)}$ Common 15.03 \$160
ationships
Shares A $\frac{17.76}{(2)}$ (3) (3) Common Stock 17.76 A $\frac{15.03}{(2)}$ (3) (3) Common Stock 15.03

Dunsire Deborah 2525 DUPONT DRIVE IRVINE, CA 92612

Signatures

/s/ Matthew J. Maletta, Attorney-in-Fact for Deborah Dunsire

**Signature of Reporting Person

05/07/2014

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

Х

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Converts to common stock on a 1-for-1 basis.

(2) Phantom stock units acquired under the Allergan, Inc. Deferred Directors' Fee Program.

(3) Phantom stock units are to be settled 100% in common stock upon the Reporting Person's retirement as an Allergan, Inc. director.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.